Knowthestock.com
AGIO - Agios Pharmaceuticals Inc

Sell

Moderate Growth and ImprovingStock Price Very High
WeakStrong
WeakStrong

45%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 25.96%
Operating Income is Negative
Net Income turning Positive
Earnings Per Share (EPS) turning Positive
Net Margin is 1798.26%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 18.5
Debt Ratio is 0.06
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Agios Pharmaceuticals Inc (AGIO) - http://www.agios.com/
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Jacqualyn Fouse
Employees - 883
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.